Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioDlink International CoHKSE:01875 62 Piotroski F-Score is 4 as of Aug. 23, 2026, which is at its 10-year median of 4.00. GuruFocus rates HKSE:01875 with a GF Score™ of 62/100 and a GF Value™ of HK$1.47 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,340 Biotechnology companies, BioDlink International Co ranks better than 73.51% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
BioDlink International Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for BioDlink International Co's Piotroski F-Score or its related term are showing as below:
HKSE:01875'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 4 Max: 7
Current: 4
During the past 9 years, the highest Piotroski F-Score of BioDlink International Co was 7. The lowest was 2. And the median was 4.
BioDlink International Co (HKSE:01875) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
BioDlink International Co Piotroski F-Score Related Terms
BioDlink International Co Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01875 vs VRTX, REGN, RVMD: Piotroski F-Score Comparison
For the Biotechnology subindustry, BioDlink International Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioDlink International Co Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioDlink International Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where BioDlink International Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
BioDlink International Co's current Net Income (TTM) was -110.9.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
BioDlink International Co's current Cash Flow from Operations (TTM) was 17.8.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
BioDlink International Co's return on assets of this year was -0.0688322. BioDlink International Co's return on assets of last year was 0.02379028.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
BioDlink International Co's gearing of this year was 0.24273012. BioDlink International Co's gearing of last year was 0.21860572.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
BioDlink International Co's current ratio of this year was 2.05076797. BioDlink International Co's current ratio of last year was 1.78946538.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
BioDlink International Co's number of shares in issue this year was 725.197. BioDlink International Co's number of shares in issue last year was 725.197.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
BioDlink International Co's gross margin of this year was 0.52027261. BioDlink International Co's gross margin of last year was 0.71238429.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
BioDlink International Co's asset turnover of this year was 0.51272911. BioDlink International Co's asset turnover of last year was 0.75177951.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
1
+
0
+
1
+
0
+
1
+
1
+
0
+
0
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
BioDlink International Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.
BioDlink International Co (HKSE:01875) has a Piotroski F-Score of 4 as of Aug. 23, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on BioDlink International Co and its competitors. This is near median its historical median of 4.00. Over the past decade, BioDlink International Co's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, BioDlink International Co ranks #355 out of 1340 companies in the Biotechnology industry, placing it in the top 26.5%.
Is BioDlink International Co's Piotroski F-Score too high?
BioDlink International Co's current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Biotechnology industry median Piotroski F-Score is 3.00. BioDlink International Co's value of 4 is 33.3% above this industry median. Based on the distribution chart, BioDlink International Co ranks #355 out of 1340 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioDlink International Co has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioDlink International Co's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioDlink International Co ranks #355 out of 1340 companies for Piotroski F-Score. This puts BioDlink International Co in the upper half of its industry. The industry median Piotroski F-Score is 3.00. BioDlink International Co's value of 4 is 33.3% above this benchmark. Historically, BioDlink International Co's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, BioDlink International Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,340 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioDlink International Co's current Piotroski F-Score of 4 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on BioDlink International Co and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioDlink International Co's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioDlink International Co stock overvalued right now?
Based on GuruFocus' analysis, BioDlink International Co (HKSE:01875) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$1.47, compared to a current price of HK$4.02 — trading 173.5% above its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 33.3% above the Biotechnology industry median of 3.00. BioDlink International Co's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For BioDlink International Co (HKSE:01875), the current Piotroski F-Score is 4 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioDlink International Co (HKSE:01875) Overvalued in 2026?
Based on GuruFocus' analysis, BioDlink International Co stock appears to be overvalued.
The current stock price of HK$4.02 is trading 173.5% above its estimated GF Value™ of HK$1.47.
GuruFocus considers BioDlink International Co to be Significantly Overvalued.
Key valuation signals for HKSE:01875:
Piotroski F-Score: 4 (near median its 10-year median of 4.00)
GF Value™: HK$1.47 vs. price of HK$4.02 (173.5% above fair value)
Industry Position: 33.3% above the Biotechnology median (#355 of 1340)
No single metric tells the full story. See the HKSE:01875 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioDlink International Co Ltd is an investment holding company. The Company is mainly engaged in research and development (R&D), manufacturing, and marketing of anti-tumor drugs, contract development and manufacturing organization (CDMO), contract manufacturing organization (CMO) business and license-out of self-developed biological drugs. The company has presence in Mainland China, and Others. The company's services includes ADC R&D Service Platform, Chemical based conjugation process development, Developability assessment for drug product, Drug substance analysis, Antibody Manufacturing, Drug product analysis, etc.
62GF Score
Get the complete analysis for HKSE:01875
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01875 has been successfully added to your 
